At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 68 enrolled
Drug / intervention
Gabapentin gelatin capsules 300mg +1 moredrug
Likely dose
Gabapentin gelatin capsules 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction
In Brief
A Phase 2 clinical trial evaluating Gabapentin gelatin capsules 300mg and Placebo for COVID-19 and 4 related conditions. Completed, enrolled 68 participants across 1 site.
Detailed Summary
This study will investigate the efficacy of oral gabapentin in olfactory improvement following Covid-19- associated olfactory dysfunction. This is a randomized, double-blinded, placebo-controlled trial.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19, Olfactory Disorder, Anosmia, Hyposmia, Parosmia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartJan 2022
First PostedJan 2022
Primary CompletionAug 2023
TodayJul 2026
First PostedJan 11, 2022
Enrollment StartJan 10, 2022
Primary CompletionAug 29, 2023
TodayJul 1, 2026
Enrollment to primary: 1.6 yearsPosted 4.5 years ago
Interventions
Gabapentin gelatin capsules 300mgdrug
Gabapentin is an anti-epileptic also used for nerve pain. This study will investigate the efficacy of gabapentin for olfactory nerve recovery and improvement in post-Covid-19 olfactory dysfunction.
Placebodrug
lactose monohydrate NF